Skip to search formSkip to main contentSkip to account menu

brequinar sodium

Known as: Sodium 6-Fluoro-2-(2'-fluoro-4-biphenylyl)-3-methyl-4-quinolinecarboxylate 
The sodium salt form of Brequinar. Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis. This… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

DuP 785
NCIt Antineoplastic Agent Terminologybrequinar

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
Asthma refractory to glucocorticoids: The role of newer immunosuppressants
1994
1994
Combination therapy with Brequinar sodium and cyclosporine synergistically prolongs hamster-to-rat cardia xenograft survival.
The accelerated rejection of hamster cardiac xenografts by Lewis rat recipients is due primarily to a humoral immune response… 
Review
1993
Review
1993
Brequinar sodium: monitoring immunosuppressive activity.
There has been remarkable consistency in our laboratory for the experimental results derived from a variety of allogeneic and… 
1993
1993
THE PREVENTION OF ACCELERATED CARDIAC ALLOGRAFT REJECTION IN SENSITIZED RECIPIENTS AFTER TREATMENT WITH BREQUINAR SODIUM
Brequinar sodium (BQR) is a novel immunosuppressive agent that is highly effective in preventing B lymphocyte-mediated antibody… 
Review
1993
Review
1993
Prevention of vascularized allograft and xenograft rejection in rodents by brequinar sodium.
The data that has been obtained from preclinical studies in rodents demonstrate that BQR is an effective primary… 
Review
1993
Review
1993
Mycophenolate mofetil and brequinar sodium: new immunosuppressive agents.
Our results demonstrate the potent immunosuppressive activity of combination MM and BQR therapy to prolong allograft survival. In… 
1993
1993
Inhibition of the pyrimidine biosynthetic pathway with S-8660, an analogue of brequinar sodium, prolongs cardiac allograft survival in rats.
The compound S-8660 is a member of a family of antiproliferative drugs that act on de novo pyrimidine synthesis through selective… 
Highly Cited
1992
Highly Cited
1992
Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study.
In a European joint project carried out in 6 laboratories a disease-oriented program was set up consisting of a panel of 7 tumor… 
1989
1989
Self-association and solubility behaviors of a novel anticancer agent, brequinar sodium.
To aid in the selection of appropriate excipients to formulate brequinar sodium [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3… 
1989
1989
Mucocutaneous side effects of brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesis
Brequinar sodium (NSC 368390; DUP 785) is a new inhibitor of pyrimidine de novo biosynthesis which has completed Phase I clinical… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)